Monitor for a subsequent pricing or prospectus supplement filing that would disclose offering size, price, and timing. The effectiveness creates potential for near-term share issuance, which could lead to dilution if equity is sold.
PRTA drugs
PRTA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $9.36entry
- T+1 · 9mo ago +5.34%α +4.58% · $9.86
- T+5 · 8mo ago +4.38%α +4.86% · $9.77
- T+20 · 8mo ago +3.85%α +8.25% · $9.72
- T+60 · 6mo ago +7.16%α −3.16% · $10.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Analysis based on filing metadata only, document content was unavailable. This is an EFFECT filing, indicating that a previously filed registration statement (likely a shelf registration) has become effective, allowing Prothena to issue securities immediately. No financial details or offering terms are available in the provided documents.
Key Facts
- EFFECT filing indicates a registration statement has become effective as of March 2, 2026
- SEC File Number: 333-277290, suggesting this relates to a prior Form S-3 or F-3 registration
- Company is based in Dublin, Ireland and operates in the life sciences sector
- No offering size, pricing, or use of proceeds disclosed in available documents
- Filing does not indicate whether this is an IPO, follow-on, or shelf takedown
Financial Impact
Not specified
Risk Factors
- Potential for unexpected equity issuance under the shelf registration, leading to dilution
- Lack of transparency on offering terms increases uncertainty for shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-000697 |
| Document: 9999999995-26-000697-index.html | 9999999995-26-000697 |
| Document: 9999999995-26-000697.txt | 9999999995-26-000697 |
Track record
20 reports on PRTA
8 of 12 bullish or bearish reports moved the stock their way by T+1. Best: +14.11% at T+60 after the Jun 12, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago 3 Neutral 1/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $8.16 to $7.97 Now $7.97 −2.33% ▼ −2.33% −0.42% vs SPY
- Nov 10, 20266d ago Insider Buy Bullish 5/10 Entry $8.56 to $8.73 Now $7.97 −6.89% ▲ +1.99% +0.67% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $7.97 to $8.78 Now $7.97 −0.00% ▲ +10.10% +7.73% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $8.47 to $8.29 Now $7.97 +5.90% ▲ +2.13% +1.65% vs SPY
- Oct 26, 202621d ago Insider Buy Bullish 5/10 Entry $8.81 to $9.10 Now $7.97 −9.53% ▲ +3.29% +2.95% vs SPY
- Oct 15, 20264w ago Insider Buy Bullish 5/10 Entry $8.35 to $8.48 Now $7.97 −4.55% ▲ +1.56% +1.13% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $8.54 to $8.36 Now $7.97 −6.67% ▼ −2.11% −2.85% vs SPY
- Sep 29, 20266w ago Insider Buy Bullish 5/10 Entry $8.38 to $8.54 Now $7.97 −4.89% ▲ +1.91% +1.73% vs SPY
- Sep 21, 20268w ago Insider Buy Bullish 6/10 Entry $8.99 to $8.68 Now $7.97 −11.35% ▼ −3.45% −2.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers